'My Sister's Keeper'

"My Sister's Keeper"

New Line Cinema

In theaters (released June 26)

The premise

Three-year-old Kate Fitzgerald is diagnosed with promyelocytic leukemia after her mother, Sara Fitzgerald (Cameron Diaz), spots bruises on her back. Despite chemotherapy, her leukemia continues to recur. She requires a bone marrow transplant, but her parents and her brother are not compatible (her doctor says the chance of a match is only 1 in 200).

The parents choose to have another child, using in vitro fertilization and pre-implantation genetics to ensure that the offspring, Anna (Abigail Breslin), is a 100% match. Anna becomes her sister's perpetual donor over the next 11 years: donating umbilical cord blood, whole blood, bone marrow (twice), blood stem cells (twice), white blood cells (lymphocytes and granulocytes) and growth hormone -- all without her permission.

At age 11, Anna is asked to donate a kidney when Kate (Sofia Vassilieva) is close to death and going into renal failure, but neither sister wants to go ahead with it. Anna consults an attorney, who fights for her "medical emancipation."

The medical questions

How common is promyelocytic leukemia and what is the prognosis in young children? What role does donation of blood products play? Could pre-implantation genetics be used to create a compatible sibling donor? Would a patient such as Kate receive growth hormone? Could an 11-year-old refuse to donate a kidney, or would she have to be "medically emancipated" first? Would a patient with recurrent acute leukemia be considered as a recipient for such a transplant?

The reality

Acute promyelocytic leukemia, in which immature granulocyte precursor cells become malignant, is very rare, as the film suggests, representing just 4% to 8% of all cases of acute myelogenous leukemia, or cancer of the blood and bone marrow.

Although the disease can be deadly, the movie is completely unrealistic in portraying it as so difficult to treat, says Dr. William Carroll, director of the New York University Cancer Institute and the Pediatric Hematology Oncology program at NYU Langone Medical Center. Retinoic acid and arsenic are standard treatments and lead to cures or prolonged remissions in more than 75% of patients. "Bone marrow transplant in this type of childhood leukemia is reserved for the rare patients that relapse," adds Dr. Christopher Dvorak, assistant professor of pediatric blood and marrow transplantation at UC San Francisco and lead author of a landmark study on the topic.